2025: Four Keywords, Capturing the Defining Moments of Dunwill Medical
Looking back at 2025, for Dunwill Medical, it was a year intertwined with dedication, breakthroughs, and empathy.
Anchored by "Originality", carving paths in scientific frontiers; bridged by "Translation", building the value channel from research to clinic; echoed by "Recognition", witnessing the dual affirmation of time and the market for perseverance; and underpinned by "Warmth", infusing a soft light of humanity beyond technological rationality.
These four keywords not only encapsulate the highlights of 2025 but also reflect Dunwill Medical's contemplation and response to "why we set out" and "where we are headed".
Deepening Technological Innovation in the CTC Field
Originality
Dunwill Medical continued to focus on the field of Circulating Tumor Cells (CTC). This year, through deep collaboration with top-tier clinical and scientific research teams, Dunwill Medical achieved original breakthroughs in two dimensions: fundamental mechanism exploration and AI-empowered applications.
Collaborating with the team of Professor Sun Yunfan from the Department of Liver Surgery, Zhongshan Hospital, Fudan University, a study published in Journal of Hepatology for the first time revealed the specific high expression of SGK1 in metastatic hepatocellular carcinoma lesions and its mechanism mediating immune evasion, providing new insights for overcoming immune resistance and expanding the application boundaries of CTCs in dynamically monitoring the evolution of the tumor microenvironment.
In collaboration with the team of Professor Yang Xinrong from the Department of Liver Surgery, Zhongshan Hospital, Fudan University, and the team of Professor Liu Qi from the Department of Bioinformatics, School of Life Sciences and Technology, Tongji University, a research paper on an AI-based CTC morphology recognition model was published in Science Bulletin, providing a more cost-effective technical pathway for primary hospitals to carry out tumor early screening and efficacy evaluation.
Promoting "Medical-Research-Enterprise" Collaborative Innovation
The value of originality lies in its implementation. In 2025, leveraging its capabilities in IVD reagent R&D, translational lean production, and regulatory registration, Dunwill Medical successfully bridged the "last mile" for multiple cutting-edge research findings to reach the patient's bedside.
Forward-looking Layout, Translational Empowerment
Dunwill Medical engaged in deep collaboration with the team of Professor Zhong Yunshi from the Endoscopy Center of Zhongshan Hospital, Fudan University, jointly promoting the clinical translation and application of the technology for predicting precise diagnosis and treatment of colorectal cancer based on molecular characteristics of microRNA in endoscopic biopsy samples.
Simultaneously, Dunwill Medical proactively advanced its strategic layout in artificial intelligence and software algorithms, successively acquiring the software copyright for "Intelligent General Review Large Model System" from Nanfang Hospital, Southern Medical University and the invention patent for "Simplified Prognostic Scoring System for Severe Fever with Thrombocytopenia Syndrome (SFTS-Wuhan) and Its Application" from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
This series of actions not only demonstrates Dunwill Medical's forward-looking investment in the smart healthcare field but also marks its efforts to translate cutting-edge academic achievements into clinically practical technological tools, injecting sustained momentum into the intelligentization and precision of medical services.
Fruitful Outcomes, Filling Gaps
The “Human Cholangiocarcinoma 5-Gene Variant Detection Kit”, jointly developed by the teams of Academician Fan Jia and Academician Zhou Jian from Zhongshan Hospital, Fudan University, in collaboration with Dunwill Medical, was officially approved, becoming the world's first HDT product for molecular diagnosis of cholangiocarcinoma. The advent of this kit fills a global gap in this field, marking China's leap from "following" to "leading" in precise diagnosis of specific tumor subtypes.
The innovative achievement “18-Hydroxycortisol, 18-Oxocortisol, and 18-Hydroxycorticosterone Detection Kit (Liquid Chromatography-Mass Spectrometry Method)”, developed by the teams of Professor Guo Wei from the Department of Clinical Laboratory and Professor Li Xiaoying from the Department of Endocrinology, Zhongshan Hospital, Fudan University, with Dunwill Medical as the entrusted preparation and transformation enterprise, as the first approved mass spectrometry-based HDT reagent for steroids in China, provides a key tool for the precise subtyping of Primary Aldosteronism (PA).
The innovative translational achievement---"Diffuse Large B-cell Lymphoma 4-MicroRNA Detection Kit (Digital PCR Method)”---developed through the transformation of proprietary intellectual property from the team of Professor Zhao Weili at the Institute of Hematology, Ruijin Hospital, and undertaken for development by Dunwill Medical, also made its debut, providing strong support for the diagnosis and screening of complex and refractory Diffuse Large B-cell Lymphoma cases.
Collaborative Development, Setting Benchmarks
Assisted by Dunwill Medical, the Institute of Hematology, Ruijin Hospital, Shanghai saw its digital PCR-based BCR::ABL quantitative detection pass international standardization verification. This means that monitoring data for Chronic Myeloid Leukemia in China now possesses a "universal language" for global dialogue.
At the 2025 CACA Integrated Oncology Prevention and Treatment Science and Technology Innovation Competition, assisted by Dunwill Medical, the team of Professor Sun Yunfan from Zhongshan Hospital, Fudan University won third place in the clinical group finals with the project "Construction and Clinical Translation Research of a Multimodal AI Diagnostic Model Based on the miRNA7 Detection Kit."
In the same year, at the 3rd Yangtze River Delta High-Value Patent Operation Competition, supporting the patent project of Fudan University Shanghai Cancer Hospital "Marker Set, Product, System for Prognosis of Colorectal Cancer and Their Application" stood out and won the silver award.
Dual Certification from Time and the Market
Recognition
Every effort deserves to be remembered, and every breakthrough awaits an echo. In 2025, widespread recognition from authoritative institutions, the industry, and the market arrived in succession. These substantial honors serve as the best validation and encouragement for Dunwill Medical's commitment to the dual-drive path of "Originality" and "Translation."
In 2025, Dunwill Medical was successively honored with awards such as "Shanghai's First Batch of Manufacturing Industry Single Champion Enterprises", "Shanghai Technology-based SME Giant", "2024-2025 Songjiang District Quality Innovation Award", and its related project was successfully selected for the 2025 Xuhui District Medical Artificial Intelligence Application Scenarios "Unveiling the List and Taking Command" Project.
Worth mentioning is that for its systematic contributions to original biomarker development and translation, Dunwill Medical was awarded the "2025 Asia-Pacific Region Annual Original Biomarker Translation Company" award. Ms. Wen Dong, Founder and CEO of Dunwill Medical, and the company were featured in an exclusive interview by the internationally renowned life sciences media Life Sciences Review.
The Soft Light of Humanity Beyond Technological Rationality
Warmth
Technology for good, imbuing innovation with humanistic care. "Warmth" has always been the starting point and destination of all technological exploration at Dunwill Medical. In 2025, this warmth flowed through open collaboration with industry partners, attentive nurturing of team growth, and social responsibility towards public health.
Dunwill Medical received a visit from the "Bay Area Health Science and Technology Achievement Transformation Growth Camp", exploring new pathways for translation with elites from various sectors, injecting new momentum into jointly promoting the efficient translation of medical technology achievements and regional collaborative innovation.
The mid-year management meeting was guided by the "Red Boat Spirit," revisiting the entrepreneurial初心 and strengthening the sense of mission.
Throughout the year, colorful festival care and team-building activities allowed the warmth of "family" to permeate daily life, fostering an open, warm, and belonging-rich organizational atmosphere.
Together, these four keywords piece together a multidimensional and authentic portrait of Dunwill Medical in 2025.
Each insistence on originality, each dedication to translation, each recognition received, and every degree of warmth conveyed are steadfast echoes of our founding commitment: "Partnering on the Medical Journey, with Originative Quality." The past year has unfolded splendid achievements; the new year beckons us to scale even greater heights.
Vast are the mountains and seas, and the future is here. In 2026, Dunwill Medical will power the future of medicine!
